Markets:

Overview

News

Currencies

International

Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

5.240 -0.240 (-4.38%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial ↗

July 12, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 12, 2022

Via Benzinga

Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial

July 12, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap

July 11, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Why Aldeyra Therapeutics' Shares Are Soaring Today? ↗

June 08, 2022

Via Benzinga

Aldeyra Therapeutics: Q1 Earnings Insights ↗

May 05, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

June 09, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease

June 08, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease

June 07, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease

May 24, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference

May 23, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness ↗

May 18, 2022

Via Benzinga

Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness

May 18, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights

May 05, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting

May 04, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

70 Biggest Movers From Friday ↗

May 02, 2022

Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 29, 2022

Via Benzinga

48 Stocks Moving In Friday's Mid-Day Session ↗

April 29, 2022

Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:...

Via Benzinga

Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points ↗

April 29, 2022

U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Friday.

Via Benzinga

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid ↗

April 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 29, 2022

Via Benzinga

How To Attend Aldeyra Therapeutics Q1 2022 Earnings Conference Call ↗

April 29, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

Aldeyra Therapeutics Announces Chief Financial Officer Transition

April 28, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

April 27, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 21, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease

April 05, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day

March 29, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.